CD47 and neoplasm: While the employment of monotherapy, either anti-PD-L1 or anti-CD47, has facilitated the immune response, the incorporation of anti-CD47 with anti-PD-L1 has conspicuously diminished the tumor burden through the augmentation of cytotoxic T cells that secrete intratumoral granzyme B [69].